Switch theme
Sign up to access all valuation multiples
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
1987
n/a
LTM Revenue $322M
LTM EBITDA $74.7M
$456M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Blau Farmacêutica has a last 12-month revenue (LTM) of $322M and a last 12-month EBITDA of $74.7M.
In the most recent fiscal year, Blau Farmacêutica achieved revenue of $308M and an EBITDA of $70.6M.
Blau Farmacêutica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Blau Farmacêutica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $322M | XXX | $308M | XXX | XXX | XXX |
| Gross Profit | $124M | XXX | $116M | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA | $74.7M | XXX | $70.6M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $64.8M | XXX | $60.1M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $44.3M | XXX | $38.2M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $85.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Blau Farmacêutica's stock price is BRL 14 (or $2).
Blau Farmacêutica has current market cap of BRL 2.5B (or $437M), and EV of BRL 2.6B (or $456M).
See Blau Farmacêutica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $456M | $437M | XXX | XXX | XXX | XXX | $0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Blau Farmacêutica has market cap of $437M and EV of $456M.
Blau Farmacêutica's trades at 1.5x EV/Revenue multiple, and 6.5x EV/EBITDA.
Equity research analysts estimate Blau Farmacêutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Blau Farmacêutica has a P/E ratio of 9.9x.
See valuation multiples for Blau Farmacêutica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $437M | XXX | $437M | XXX | XXX | XXX |
| EV (current) | $456M | XXX | $456M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | 7.0x | XXX | 7.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.9x | XXX | 11.5x | XXX | XXX | XXX |
| EV/FCF | 9.4x | XXX | 7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBlau Farmacêutica's last 12 month revenue growth is 11%
Blau Farmacêutica's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Blau Farmacêutica's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Blau Farmacêutica's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Blau Farmacêutica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Blau Farmacêutica acquired XXX companies to date.
Last acquisition by Blau Farmacêutica was XXXXXXXX, XXXXX XXXXX XXXXXX . Blau Farmacêutica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Blau Farmacêutica founded? | Blau Farmacêutica was founded in 1987. |
| Where is Blau Farmacêutica headquartered? | Blau Farmacêutica is headquartered in Brazil. |
| Who is the CEO of Blau Farmacêutica? | Blau Farmacêutica's CEO is Mr. Marcelo Rodolfo Hahn. |
| Is Blau Farmacêutica publicy listed? | Yes, Blau Farmacêutica is a public company listed on BVMF. |
| What is the stock symbol of Blau Farmacêutica? | Blau Farmacêutica trades under BLAU3 ticker. |
| When did Blau Farmacêutica go public? | Blau Farmacêutica went public in 2021. |
| Who are competitors of Blau Farmacêutica? | Similar companies to Blau Farmacêutica include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Blau Farmacêutica? | Blau Farmacêutica's current market cap is $437M |
| What is the current revenue of Blau Farmacêutica? | Blau Farmacêutica's last 12 months revenue is $322M. |
| What is the current revenue growth of Blau Farmacêutica? | Blau Farmacêutica revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Blau Farmacêutica? | Current revenue multiple of Blau Farmacêutica is 1.4x. |
| Is Blau Farmacêutica profitable? | Yes, Blau Farmacêutica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Blau Farmacêutica? | Blau Farmacêutica's last 12 months EBITDA is $74.7M. |
| What is Blau Farmacêutica's EBITDA margin? | Blau Farmacêutica's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Blau Farmacêutica? | Current EBITDA multiple of Blau Farmacêutica is 6.1x. |
| What is the current FCF of Blau Farmacêutica? | Blau Farmacêutica's last 12 months FCF is $48.3M. |
| What is Blau Farmacêutica's FCF margin? | Blau Farmacêutica's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Blau Farmacêutica? | Current FCF multiple of Blau Farmacêutica is 9.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
